Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New pharmaceutical use of dexmedetomidine

A dexmedetomidine and pharmaceutical technology, which is applied in the field of new drug application of dexmedetomidine, can solve the problems of unclear prognosis of elderly postoperative patients, achieve the improvement of the percentage of non-rapid eye movement sleep in stage 2, and prolong the total sleep period. Sleep time, effect of improving sleep efficiency

Inactive Publication Date: 2015-07-22
PEKING UNIV FIRST HOSPITAL
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But whether it can improve sleep in elderly postoperative patients, and improve the prognosis of elderly postoperative patients by improving sleep is not clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New pharmaceutical use of dexmedetomidine
  • New pharmaceutical use of dexmedetomidine
  • New pharmaceutical use of dexmedetomidine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Embodiment 1, the impact of low dose dexmedetomidine on postoperative sleep in elderly patients

[0057] Our small randomized, double-blind, placebo-controlled study included 76 patients aged 65 years or older who were admitted to the ICU after noncardiac surgery and did not require mechanical ventilation. Patients in the dexmedetomidine group (n=38) were given continuous intravenous infusion of dexmedetomidine hydrochloride 0.1 μg / kg / h from 5:00 p.m. =38) Infuse normal saline at the same rate at the same time. The polysomnogram was continuously recorded during the infusion of the test drug, and the subjective sleep quality of the patient was evaluated by the Numerical Rating Scale (NRS, 0=best sleep, 10=worst sleep) at 8 o'clock the next morning after the operation (see figure 1 ). Finally, 61 patients (31 in the dexmedetomidine group and 30 in the placebo group) obtained complete and analyzable polysomnograms.

[0058] The results obtained are shown in Table 1.

...

Embodiment 2

[0066] Embodiment 2, the impact of small doses of dexmedetomidine on postoperative sleep and prognosis of elderly patients

[0067] Our large randomized, double-blind, placebo-controlled study of 700 patients aged 65 years or older admitted to the ICU after noncardiac surgery (383 patients received mechanical ventilation and 317 patients did not require mechanical ventilation) . Patients in the dexmedetomidine group (n=350) were continuously infused with dexmedetomidine hydrochloride 0.1 μg / kg / h from 5:00 p.m. =350) infuse normal saline at the same speed at the same time. The Numerical Rating Scale (NRS, 0=best sleep, 10=worst sleep) was used to evaluate the patient’s subjective sleep quality at 8 am every day for the first 3 days after operation, and the Numerical Rating Scale (NRS, 0=no pain at all, 10=worst sleep) was used to evaluate the patient’s subjective sleep quality. = worst pain) to rate the patient's pain level (see figure 2 ); the first 7 days after operation,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new use of dexmedetomidine. The new use of the dexmedetomidine or its pharmaceutically acceptable salt provided by the invention refers to application in preparation of: 1) products for prevention and / or treatment of postoperative sleep disorders; 2) products for prevention and / or reduction of postoperative complications; and 3) products for improvement of postoperative determination. Efficacy tests show that for the elderly non-cardiac surgery patients, small dose dexmedetomidine intravenous infusion can significantly improve the postoperative sleep structure and subjective sleep quality, and at the same time can improve patient prognosis, which includes lowering pain degree, reducing postoperative delirium and non-delirium complications and shortening ICU retention time.

Description

technical field [0001] The invention relates to a new drug application of dexmedetomidine. Background technique [0002] Dexmedetomidine is a highly selective α2 adrenergic receptor agonist, its chemical name is: (S)-4-[1-(2,3-dimethylphenyl)ethyl ]-1H-imidazole, its molecular formula is: C 13 h 16 N 2 . Clinically, dexmedetomidine mainly produces sedative, analgesic and antisympathetic effects, which are the result of its stimulation of α2 adrenergic receptors in different parts: stimulation of brainstem locus coeruleus nucleus receptors mainly produces sedation, stimulation of spinal cord receptors The body mainly produces analgesic effect, and the stimulation of medullary receptor mainly produces antisympathetic effect[1,2]. [0003] Dexmedetomidine currently in clinical use is the injection preparation of its hydrochloride, which is mainly used for sedation of ICU mechanically ventilated patients and adjuvant medication for perianesthesia patients, the latter includ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4174A61P25/20A61P9/10A61P9/06A61P11/00A61P13/12A61P17/02A61P1/00A61P7/04A61P13/02A61P25/00A61P9/02A61P9/12
Inventor 王东信
Owner PEKING UNIV FIRST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com